Nevro (NYSE:NVRO) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Nevro (NYSE:NVRO) in a research note issued on Tuesday. The brokerage set a “hold” rating on the medical equipment provider’s stock.

Other equities research analysts also recently issued research reports about the stock. Truist Financial reduced their target price on shares of Nevro from $7.00 to $4.70 and set a “hold” rating on the stock in a research note on Wednesday, December 18th. Canaccord Genuity Group upped their price objective on shares of Nevro from $4.00 to $5.85 and gave the stock a “hold” rating in a research note on Friday, February 7th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $7.00 price objective on shares of Nevro in a report on Tuesday, November 12th. JMP Securities reissued a “market perform” rating on shares of Nevro in a report on Tuesday, November 12th. Finally, Jefferies Financial Group raised Nevro from an “underperform” rating to a “hold” rating and raised their price target for the company from $4.50 to $5.85 in a report on Monday, February 10th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and one has assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $6.43.

Nevro Price Performance

Nevro stock opened at $5.72 on Tuesday. The business has a 50 day simple moving average of $4.48 and a 200 day simple moving average of $4.98. The company has a debt-to-equity ratio of 0.67, a current ratio of 5.02 and a quick ratio of 3.76. The company has a market capitalization of $214.14 million, a PE ratio of -3.02 and a beta of 0.91. Nevro has a one year low of $3.16 and a one year high of $17.63.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Amundi acquired a new stake in shares of Nevro during the fourth quarter worth $30,000. Oxford Asset Management LLP acquired a new position in shares of Nevro during the 4th quarter worth about $39,000. Corton Capital Inc. bought a new stake in shares of Nevro in the 4th quarter valued at about $43,000. Headlands Technologies LLC acquired a new stake in shares of Nevro in the 4th quarter valued at approximately $45,000. Finally, Ieq Capital LLC bought a new position in Nevro during the 4th quarter worth approximately $46,000. 95.52% of the stock is currently owned by institutional investors and hedge funds.

About Nevro

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.